Corcept Therapeutics' Lyon sells 4,744 shares

Q: What CORT stock options did the officer exercise, and when do they expire?

Joseph Douglas Lyon exercised options for 810 shares on October 1, 2026, at $13.56 per share, and for 3,357 shares at $13.56 and 5,833 shares at $19.26 on October 2, 2026. The options were fully exercisable. The $13.56 options expire February 7, 2030, and the $19.26 options expire February 2, 2032.

The reported sales were made under a Rule 10b5-1 plan adopted June 10, 2026, with each sale's weighted-average price reported separately.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Corcept Therapeutics Chief Accounting & Technology Officer Joseph Douglas Lyon exercised options for 810 shares at $13.56 per share on October 1, 2026, and for 3,357 shares at $13.56 and 5,833 shares at $19.26 on October 2, 2026. He sold 810 shares at a weighted-average $115.3985 per share on October 1, 2026, and sold 4,446 shares at $115.6970 and 4,744 shares at $116.5407 per share on October 2, 2026. The sales were made under a Rule 10b5-1 plan adopted June 10, 2026.

Insider Trade Summary 10b5-1

Exercise and Sale: 10,000 shares ($992K approx. pre-tax spread)

Exercise and Sale 9 txns

Insider Lyon Joseph Douglas

Role See Remarks

Sold 10,000 shs ($1.16M)

Approx. gross sale proceeds $1.16M

Approx. exercise cost $169K

Approx. pre-tax spread $992K

Type	Security	Shares	Price	Value
Exercise	Stock option (right to buy) ^F6	3,357	$0.00	$0.00
Exercise	Stock option (right to buy) ^F6	5,833	$0.00	$0.00
Exercise	Common Stock ^F1	3,357	$13.56	$46K
Exercise	Common Stock ^F1	5,833	$19.26	$112K
Sale	Common Stock ^{F2, F4, F1}	4,446	$115.697	$514K
Sale	Common Stock ^{F2, F5, F1}	4,744	$116.5407	$553K
Exercise	Stock option (right to buy) ^F6	810	$0.00	$0.00
Exercise	Common Stock ^F1	810	$13.56	$11K
Sale	Common Stock ^{F2, F3, F1}	810	$115.3985	$93K

Holdings After Transaction: Stock option (right to buy) — 44,167 contracts (Direct); Common Stock — 5,683 shares (Direct)

Footnotes (6)

F1. Includes 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 537 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 130 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F2. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 10, 2026 in effect at the time of this transaction.
F3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.23 to $115.615 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F4. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.23 to $116.21 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F5. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.25 to $116.98 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F6. Fully exercisable.

Key Figures

Option exercise: 810 shares at $13.56 per share Option exercise: 3,357 shares at $13.56 per share Option exercise: 5,833 shares at $19.26 per share +3 more

6 metrics

Option exercise 810 shares at $13.56 per share October 1, 2026

Option exercise 3,357 shares at $13.56 per share October 2, 2026

Option exercise 5,833 shares at $19.26 per share October 2, 2026

Weighted-average sale price $115.3985 per share 810 shares sold October 1, 2026

Weighted-average sale price $115.6970 per share 4,446 shares sold October 2, 2026

Weighted-average sale price $116.5407 per share 4,744 shares sold October 2, 2026

Key Terms

Rule 10b5-1 plan, weighted average sale price, Fully exercisable, unvested restricted stock awards

4 terms

Rule 10b5-1 plan financial

"made pursuant to a 10b5-1 plan"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted average sale price financial

"weighted average sale price for the entire number of shares sold"

Fully exercisable financial

"Fully exercisable"

unvested restricted stock awards financial

"shares underlying unvested restricted stock awards"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CORT shares did its Chief Accounting & Technology Officer sell?

Joseph Douglas Lyon, Corcept Therapeutics' Chief Accounting & Technology Officer, sold 810 shares on October 1, 2026, at a weighted-average $115.3985 per share, and on October 2, 2026, sold 4,446 shares at $115.6970 and 4,744 shares at $116.5407 per share. The sales were made under a Rule 10b5-1 plan adopted June 10, 2026.

What CORT stock options did the officer exercise, and when do they expire?

Joseph Douglas Lyon exercised options for 810 shares on October 1, 2026, at $13.56 per share, and for 3,357 shares at $13.56 and 5,833 shares at $19.26 on October 2, 2026. The options were fully exercisable. The $13.56 options expire February 7, 2030, and the $19.26 options expire February 2, 2032.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/05/2026 - 07:54 PM Accepted by SEC EDGAR 10/05/2026 - 07:54 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lyon Joseph Douglas

(Last)

(First)

(Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY

CALIFORNIA

94065

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/01/2026		M		810	A	$13.56	6,493⁽¹⁾	D
Common Stock	10/01/2026		S⁽²⁾		810	D	$115.3985⁽³⁾	5,683⁽¹⁾	D
Common Stock	10/02/2026		M		3,357	A	$13.56	9,040⁽¹⁾	D
Common Stock	10/02/2026		M		5,833	A	$19.26	14,873⁽¹⁾	D
Common Stock	10/02/2026		S⁽²⁾		4,446	D	$115.697⁽⁴⁾	10,427⁽¹⁾	D
Common Stock	10/02/2026		S⁽²⁾		4,744	D	$116.5407⁽⁵⁾	5,683⁽¹⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock option (right to buy)	$13.56	10/01/2026		M			810	⁽⁶⁾	02/07/2030	Common Stock	810	$0.00	3,357	D
Stock option (right to buy)	$13.56	10/02/2026		M			3,357	⁽⁶⁾	02/07/2030	Common Stock	3,357	$0.00	0	D
Stock option (right to buy)	$19.26	10/02/2026		M			5,833	⁽⁶⁾	02/02/2032	Common Stock	5,833	$0.00	44,167	D

Explanation of Responses:

1. Includes 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 537 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 130 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

2. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 10, 2026 in effect at the time of this transaction.

3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.23 to $115.615 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

4. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.23 to $116.21 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

5. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.25 to $116.98 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

6. Fully exercisable.

Remarks:

Chief Accounting & Technology Officer

	/s/ Joseph Douglas Lyon	10/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR